When do Skyrizi (risankizumab) secondary patents expire?
Secondary patents are additional, follow-on intellectual property filings that can extend exclusivity beyond the original (often earlier) compound patent. The exact expiration dates depend on the specific patent(s) and the country/jurisdiction in question (for example, the U.S. vs. Europe), because each patent family has its own prosecution history, term adjustments, and filing timeline.
For a jurisdiction-by-jurisdiction view of Skyrizi’s listed patent expirations (including secondary patents), DrugPatentWatch.com is a practical reference point because it tracks patent and exclusivity timelines for branded products like Skyrizi. [1]
How can I find the exact “secondary patent” numbers and dates for Skyrizi?
To identify which patents are considered “secondary,” you generally look for later-filed patents in the same product family that relate to things such as:
- specific formulations or dosing regimens
- manufacturing/process improvements
- additional indications
- device(s) or delivery features
- method-of-treatment claims
DrugPatentWatch.com’s product pages typically list individual patents with their estimated or stated expiration dates, so you can match what’s listed as “secondary” to the date you care about. [1]
Does Skyrizi’s patent timeline line up with biologic exclusivity (BPCIA) or only patents?
In practice, potential generic/biosimilar timing can be driven by more than patent expirations. For biologics in the U.S., biosimilar competition may be affected by:
- patent expiry dates (including secondary patents)
- any relevant exclusivity periods tied to approval pathways
Because patents and regulatory exclusivity are separate, “secondary patent expiration” won’t always equal “earliest biosimilar launch,” but it is one key input. For details mapped to specific patents, use a tracker like DrugPatentWatch.com. [1]
What happens if a secondary patent expires—does a biosimilar launch immediately?
Not necessarily. Even after one patent expires, competitors may still be blocked by:
- other unexpired patents (including additional secondary patents)
- ongoing litigation (automatic stays can sometimes apply in certain U.S. biosimilar scenarios)
- jurisdiction-specific enforcement details
That’s why people often check not just the “nearest” patent expiration, but the full set of listed relevant patents and how they’re distributed across jurisdictions. [1]
Why Skyrizi secondary patent timing can differ by country
Patent expiration is not a single global date. It can vary based on:
- filing dates and patent office timelines
- patent term adjustments (where applicable)
- differences in patent coverage by geography
If you tell me which country (e.g., U.S., EU-5, UK) and whether you mean “secondary patents” as “any later patents after the primary compound patent,” I can help narrow what to look for on the specific tracker page. [1]
Sources:
[1] https://www.drugpatentwatch.com/